Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: A case report.
cholangiocarcinoma
microsatellite instability‐high
pembrolizumab
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
16
01
2021
revised:
13
02
2021
accepted:
21
02
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
The tumor reduction effect of pembrolizumab is extremely high compared to standard chemotherapy and might show prolonged survival. Therefore, the MSI status should be examined in patients with cholangiocarcinoma.
Identifiants
pubmed: 33936676
doi: 10.1002/ccr3.4008
pii: CCR34008
pmc: PMC8077359
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2259-2263Informations de copyright
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Lancet Oncol. 2016 Jun;17(6):717-726
pubmed: 27157491
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Cancer Chemother Pharmacol. 2015 Feb;75(2):293-300
pubmed: 25477010
Cancer Res Treat. 2020 Apr;52(2):594-603
pubmed: 32019287
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Anticancer Res. 2020 Jul;40(7):4123-4129
pubmed: 32620661
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5):
pubmed: 28619747
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
J Clin Med. 2020 Jun 07;9(6):
pubmed: 32517311
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Intern Med. 2020 Sep 15;59(18):2261-2267
pubmed: 32536644